Inclusion Criteria:

- Advanced solid tumor malignancy for which there is no potentially curative treatment;
in the breast cancer expansion cohort, patients must have a documented history of
invasive ductal or lobular cancer, unresponsive to at least 1 line of systemic
therapy in the metastatic setting; there is no limit to the number of prior lines of
therapy

- Performance status Eastern Cooperative Oncology Group (ECOG) equal or less than 2

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 5 x upper
institutional limit (ULN)

- Total bilirubin =< 1.5 ULN

- Creatinine clearance (CrCl) >= 45 as measured by the standard Cockcroft-Gault
equation

- Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 (if not due to
anticoagulants)

- White blood cell count (WBC) >= 3.0

- Absolute neutrophil count (ANC) >= 1.5

- Platelets >= 80,000

- Hemoglobin (Hgb) >= 8.5

- Prior toxicities are allowed as long as they are stable and would not interfere with
study drug toxicity assessment

- Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors
(RECIST) (v 1.1) criteria

- Ability to understand and the willingness to sign a written informed consent
document; a signed informed consent must be obtained prior to any study specific
procedures

- Women of childbearing potential must have a negative pregnancy test performed within
7 days prior to the start of treatment; women of childbearing potential and men must
agree to use a medically accepted form of birth control for the duration of study
participation; men must agree to use a medically accepted form of birth control for 2
months following completion of study treatment

Exclusion Criteria:

- Any investigational agent within 4 weeks or 5 half-lives, whichever is longer, of
first dose of study treatment

- Unwillingness or inability to take folic acid, vitamin B12 supplementation, or
dexamethasone

- Known or presumed intolerance of pemetrexed or sorafenib; unable to swallow
medication; suspected malabsorption

- Active illicit substance or alcohol abuse

- Contraindication to antiangiogenic agents, including:

- Pulmonary hemorrhage/bleeding event >= Grade 2 within 4 weeks or less prior to the
first dose of study drug

- Any other hemorrhage/bleeding event >= Grade 3 within 4 weeks or less prior to the
first dose of study drug

- Serious non-healing wound, ulcer, or bone fracture

- Thrombolic or embolic events such as a myocardial infarction, cerebrovascular
accident including transient ischemic attacks within the past 6 months

- Major cardiac dysfunction, such as uncontrolled angina, congestive heart failure with
New York Heart Association (NYHA) class III or higher, ventricular arrhythmias
requiring anti-arrhythmic therapy

- Systolic blood pressure > 160 mmHg or diastolic pressure > 100 mmHg despite optimal
medical management

- Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5
day period

- Serious uncontrolled infection > Common Terminology Criteria for Adverse Events
(CTCAE) (v 4) grade 2

- Uncontrolled metastatic brain disease

- Other condition(s) that in the opinion of the investigator might compromise the
objectives of the study